OXFORD BIOMEDICA
PLC
Oxford BioMedica Completes Acquisition of Novel Antibody
Technology
Oxford
BioMedica plc (AIM-OXB) today announced that it has strengthened
its cancer immunotherapy programme through the acquisition
of rights to a novel human antibody, called OBAb2.
The
antibody has significantly higher specificity for tumours
than many so-called tumour specific antibodies. The rights
for it have been acquired from a leading research group
led by Dr Hennie Hoogenboom at the University of Maastricht
in the Netherlands.
Oxford
BioMedica is establishing a world-wide reputation for advanced
gene-based immunotherapy for cancer. Its first product in
this area, TroVaXT, has entered clinical development and
will be tested in Phase I/II trials in colorectal cancer.
In addition, the Company is developing gene-based antibody
therapies to be used alongside the TroVaXT vaccine. The
OBAb2 antibody is part of the Company's armoury of engineered
antibodies that are to be delivered by gene therapy.
Commenting
on the agreement, Alan Kingsman, CEO of Oxford BioMedica
said: " Oxford BioMedica has accumulated a powerful set
of technologies that target the treatment of cancer by recruiting
the immune system to destroy the tumour. There is substantial
interest in these technologies from the pharmaceutical industry
and I am confident OBAb2 will be a major deal-driver in
the future."
|
